FORM 13-502F2
CLASS 2 REPORTING ISSUERS – PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, Donald Gordon, an officer of the reporting issuer noted below have examined this Form 13-502F2 (the **Form**) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

(s) _____ June 19, 2020
Name: Donald Gordon Date:
Title: CFO, Director

Reporting Issuer Name: BioHep Technologies Ltd.

End date of previous financial year: January 31, 2020

Financial Statement Values:
(Use stated values from the audited financial statements of the reporting issuer as of the end of its previous financial year)

Retained earnings or deficit	$ 2,077,092.00	(A)
Contributed surplus	$ 0	(B)
Share capital or owners' equity, options, warrants and preferred shares (whether such shares are classified as debt or equity for financial reporting purposes)	$ 614,845.00	(C)
Non-current borrowings (including the current portion)	$ 0	(D)
Finance leases (including the current portion)	$ 0	(E)
Non-controlling interest	$ 0	(F)
Items classified on the statement of financial position as non-current liabilities (and not otherwise listed above)	$ 0	(G)
Any other item forming part of equity and not set out specifically above	$ -703,416.00	(H)

Capitalization for the previous financial year (Add items (A) through (H))	$ 1,988,521.00
Participation Fee (From Appendix A of OSC Rule 13-502 *Fees*, select the participation fee beside the capitalization calculated above)	$ 890.00
Late Fee, if applicable (As determined under section 2.7 of OSC Rule 13-502 *Fees*)	$
Total Fee Payable (Participation Fee plus Late Fee)	$ 890.00